• HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT
Tamim Asset Management
  • HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT

Stock Insights

Talking Top Twenty | Part 4: CSL & Wesfarmers

12/5/2021

0 Comments

 
Sid Ruttala continues his journey through the ASX20. This week his notes visit and review CSL Ltd. (CSL.ASX) and Wesfarmers Ltd (WES.ASX). 
Sid Ruttala, Investment SpecialistAuthor: Sid Ruttala
If you have missed some of the earlier parts to Sid Ruttala's latest Talking Top Twenty, you can find them here:

Part 1: The Banks - CBA & WBC
Part 2: The Banks - NAB & ANZ
​​Part 3: BHP & Fortescue

​CSL Ltd (CSL.ASX)
CSL Ltd logo
Mixed results from CSL though beats on management guidance, which has historically been on the conservative side. In our previous notes, we had mentioned the likely headwinds to plasma collection as a result of Covid and the associated lockdowns. While the company did continue to expand its collection footprint across the US, it was disappointing to see a sharp decline, coming in at about 80% of 2019 volumes. Numbers wise, stellar growth across profit and revenue with revenue up 15% and NPAT up 44%. 

Looking at the results in slightly more depth, this was driven primarily by Seqris and the increased demand for seasonal influenza vaccines (+44%). Importantly, gross margins continue to increase substantially, a clear sign of management discipline. There are signs of renewed life across the Albumin product line with hospitals back to 90% capacity in China and associated increases to elective surgery. Across the hemophilia market, the numbers were a little mixed, with sales flat or in some cases declining due to competitive pressures (this was expected). Ironically, the stimulus packages in the US may have been a headwind for the company (i.e. disincentivising plasma collection primarily in lower socioeconomic households). Nevertheless, management seems to have a clear vision to grow the supply network and add on collection centres (44 to be exact). 

Going forward, however, management only reaffirmed earnings guidance of 6-10%, which implies that 12-20% of FY21 earnings will be generated in the second half. This is substantially lower than the 5-year average of 40%. A substantial decline in growth.

Picture
Red Flags & Risks: While a decline in collections was to be expected, the scale (i.e. 20%) is still daunting. Especially so when compared to competitors. Grifols (GRF.BME), CSL’s Spanish rival, has made significant strides in its plasma collection infrastructure, especially in mainland China (i.e. Shanghai). No further guidance or elucidation was given pertaining to the Vitaeris acquisition, which had at the time of acquisition been conducting Phase III trials pertaining to organ rejection within kidney transplants. The results across Asia also looked particularly messy with a decline of 9% in the Seqirus product line. Again, we reiterate the crucial nature of the APAC region for continued growth. 

My Expectations: The company continues to be a long-term hold for me. But at $274 AUD it remains fully priced and might see some volatility especially as the market digests what is likely to be a less than stellar 2H.

​Dividend Yield: 1.06% (Assuming a share price of $274.50). Expectation remains that dividends continue to grow at double digits over the long-term.  
Wesfarmers (WES.ASX)
Wesfarmers Ltd logo
​Wesfarmers continues its fantastic performance and showcases the value add of having a diverse portfolio (not many firms can pull off a conglomerate structure, i.e. GE). For those that insist that brick-and-mortar retail is dead, both Kmart and Officeworks seem to be proving otherwise (at least for now). Kmart’s revenues increased by 9% with Officeworks’ increasing 29%. Target remains a problem child, but management seems to be executing on its omnichannel strategy nevertheless with online penetration increasing to 15.9% in 1H. The numbers are similar with Kmart, increasing to 8.9%. What was interesting delving deeper into the numbers was the increased purchase size for online orders (approx. 2x), with the majority of fulfillment taking place in store.

Across the Chemicals, Energy and Fertilizers (CEF) division however, the numbers are a little less stellar with revenues declining 6.6% and an earnings decline of 7.5%. Much of this may be transitory in nature though, not least due to continued weakness in Saudi contract prices. Given our thesis around commodities such as iron ore and gold, we would hazard a guess that we will likely see a revitalisation of demand for ammonium nitrate as well as sodium cyanide (crucial for gold mining). In other news, progress has been made pertaining to the Mt Holland lithium project (JV with SQM).

Red Flags & Risks: CEF division is getting increasingly competitive, especially with Orica (ORI.ASX) opening up a new plant in Barrup. Much will be contingent on continued demand from both iron ore producers and a recovery in gold mining (closed due to Covid measures). For retail, temporary closures and continued diminishing of margins as well as rental pressures remain the key downside risks going forward. 

My Expectations: Management continues to deliver. In my previous notes, we mentioned that the failed bid for Lynas (LYS.ASX) was potentially a sign of what management’s focus is likely to be going forward. The Mt. Holland project confirms this. Though, given the trends we have seen, we still feel that Lynas would have been a great addition to the portfolio. We fully expect greater focus to be placed on CEF going forward and turning it around despite increased competition. Nevertheless, kudos to management. 

Dividend Yield: 3.31% assuming a share price of $54.29 AUD. Expectation is that this will stay stable on a nominal basis.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Stock Commentary

    At TAMIM we are committed to educating investors on how best to manage their retirement futures.

    Sign up to receive our weekly newsletter:

    * indicates required

    TAMIM Asset Management provides general information to help you understand our investment approach. Any financial information we provide is not advice, has not considered your personal circumstances and may not be suitable for you.

    Archives

    May 2022
    April 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    December 2015

    Categories

    All
    2016 Presidential Election
    5G
    AGM Season
    Apple (AAPL.NASDAQ)
    Asia Small Companies
    ASX
    ATL.AX
    Aus Equity All Cap Portfolio
    Aus Equity All Cap Value Portfolio
    Aus Equity Growth Portfolio
    Aus Equity Income Portfolio
    Aus Equity Small Cap Portfolio
    Australian Stocks
    Autonomous Vehicles
    Big Four Banks
    Brexit
    Electric Vehicles
    Emerging Markets
    Energy
    ENN.AX
    FAANG
    Financials
    Fintech
    Global Equity High Conviction Portfolio
    Global Mobility
    Gmg.ax
    Gold
    Growth Stocks
    Guy Carson
    Healthcare
    Income Investing
    Infrastructure
    International Stocks
    Investment Thematics
    IT Services
    Mergers & Acquisitions
    Mobility
    Pharma
    Property
    Rare Earths
    REITs
    Reporting Season
    Retail
    Robert Swift
    Ron Shamgar
    SLK.AX
    Small Cap Income Portfolio
    Small Caps
    Stock Report
    Takeovers
    Technology
    Telco Stocks
    Telstra (TLS.ASX)
    Tourism
    TPG
    Utilities
    Value Investing
    Video
    Wesfarmers (WES.ASX)

    RSS Feed

TAMIM | Equities | Property | Credit
​

TAMIM Fund
Australia All Cap
Australia Small Cap Income
Global Mobility
Global High Conviction
Credit

Listed Property
TAMIM Property
Company
About
Contact
Insights
Invest Online
Login
Other
Privacy Policy
Terms & 
Conditions
​Disclaimer
Contact
Level 4, 55 Grafton Street
Bondi Junction, Sydney NSW, 2022

1300 750 007

ima@tamim.com.au

DISCLAIMER

​The information provided on this website should not be considered financial or investment advice and is general information intended only for wholesale clients ( as defined in the Corporations Act). If you are not a wholesale client, you should exit the website. The content has been prepared without taking into account your personal objectives, financial situations or needs. You should seek personal financial advice before making any financial or investment decisions. Where the website refers to a particular financial product, you should obtain a copy of the relevant product services guide or offer document for wholesale investors before making any decision in relation to the product. Investment returns are not guaranteed as all investments carry some risk. The value of an investment may rise or fall with the changes in the market. Past performance is no guarantee of future performance. This statement relates to any claims made regarding past performance of any Tamim (or associated companies) products. Tamim does not guarantee the accuracy of any information in this website, including information provided by third parties. Information can change without notice and Tamim will endeavour to update this website as soon as practicable after changes. Tamim Funds Management Pty Limited and CTSP Funds Management Pty Ltd trading as Tamim Asset Management and its related entities do not accept responsibility for any inaccuracy or any actions taken in reliance upon this advice. All information provided on this website is correct at the time of writing and is subject to change due to changes in legislation. Please contact Tamim if you wish to confirm the currency of any information on the website.  

magellen, kosec, clime, wilson, wam, montgomery, platinum, commsec, caledonia, pengana, tamim

  • HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT